目的 探讨注射用生长抑素联合注射用乌司他丁治疗粘连性肠梗阻的临床疗效。方法 选取2012年2月—2017年2月北京市顺义区医院和河北省第七人民医院收治的76例粘连性肠梗阻患者作为研究对象，将患者随机分为对照组和治疗组，每组38例。对照组静脉滴注注射用乌司他丁，将10万单位乌司他丁溶于0.9%氯化钠溶液250 mL中，1次/d。治疗组在对照组治疗的基础上静脉滴注注射用生长抑素，0.25 mg/h，直到肛门恢复排便、排气。观察两组患者的临床疗效，比较两组的临床指标、血清炎性因子水平和不良反应情况。结果 治疗后，治疗组的总有效率为84.21%，显著高于对照组的68.42%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组胃肠减压量、腹胀缓解时间和排气恢复时间明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清内毒素（LPS）、超敏C反应蛋白（hs-CRP）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清炎性因子水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗期间，治疗组不良反应总发生率为7.89%，低于对照组的26.32%，两组不良反应发生率比较差异具有统计学意义（P<0.05）。结论 注射用生长抑素联合注射用乌司他丁治疗粘连性肠梗阻的具有较好的临床疗效，可显著降低患者炎症反应，不良反应低，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Somatostatin for injection combined with Ulinastatin for injection in treatment of adhesive intestinal obstruction. Methods Patients (76 cases) with adhesive intestinal obstruction in the Hospital of Shunyi District Beijing and Hebei Seventh People's Hospital from February 2012 to February 2017 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were iv administered with Ulinastatin for injection, 100 thousand U dissolved into 0.9% sodium chloride solution 250 mL, once daily. Patients in the treatment group were iv administered with Somatostatin for injection on the basis of the control group, 0.25 mg/h, until the defecation were restored in the anus. After treatment, the clinical efficacies were evaluated, and the clinical indexes, serum inflammatory factor levels, and the adverse reactions in two groups were compared. Results After treatment, the clinical efficacy in the treatment group was 84.21%, which was significantly higher than 68.42% in the control group, and there were differences between two groups (P<0.05). After treatment, the gastrointestinal decompression volume, abdominal distension relief time, and exhaust recovery time in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, the LPS and hs-CRP levels in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, the serum inflammatory factor levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). During the treatment, incidence of adverse reactions in the treatment group was 7.89%, which was lower than 26.32% in the control group, and there were differences between two groups (P<0.05). Conclusion Somatostatin for injection combined with Ulinastatin for injection has clinical curative effect in treatment of adhesive intestinal obstruction, can significantly reuduce the inflammation, with low adverse reactions, which has a certain clinical application value.